找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Drugs between Research and Regulations; Proceedings of the 5 C. Steichele (Medizinischer Direktor),U. Abshagen Conference proceedings 1985

[复制链接]
楼主: 无感觉
发表于 2025-3-23 12:24:24 | 显示全部楼层
https://doi.org/10.1007/978-1-4842-4950-5sons and, at least in Italy, the law prevent the GP from taking a direct part in the first phases of clinical research; on the other hand, even after the introduction of a medicine onto the market, the general practitioner’s involvement is considered to be that of prescription rather than evaluation.
发表于 2025-3-23 16:21:52 | 显示全部楼层
Installing Third-Party Libraries,linical trials, with special reference to drug evaluation after marketing (Phase IV). I shall deal with it from the vantage of a decade and a half of consultation work in this area, especially with the Drug Epidemiology Unit of Boston University School of Medicine.
发表于 2025-3-23 19:48:03 | 显示全部楼层
Clinical guidelines — a help or a hindrance?cceed, now and again, in thwarting their deliberations and obscuring their aims. The issue of Guidelines for the Clinical Investigation of Drugs is a case in point. They are hailed by some and condemned by others and nine tenths of the problem is that the one party really has little idea what the other party is talking about.
发表于 2025-3-23 23:51:22 | 显示全部楼层
发表于 2025-3-24 03:04:13 | 显示全部楼层
Alternatives to clinical trials in post-marketing research on drug effectslinical trials, with special reference to drug evaluation after marketing (Phase IV). I shall deal with it from the vantage of a decade and a half of consultation work in this area, especially with the Drug Epidemiology Unit of Boston University School of Medicine.
发表于 2025-3-24 07:28:05 | 显示全部楼层
Managing Device Drivers and PC ResourcesRisk: benefit decision making lies at the heart of modern therapeutics, and it is possible to distinguish between four categories of problem.
发表于 2025-3-24 10:44:29 | 显示全部楼层
发表于 2025-3-24 14:49:36 | 显示全部楼层
The organisation of long-term intervention and prevention studiesRisk: benefit decision making lies at the heart of modern therapeutics, and it is possible to distinguish between four categories of problem.
发表于 2025-3-24 20:33:56 | 显示全部楼层
发表于 2025-3-25 00:30:33 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-19 22:03
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表